BTIG Maintains Buy on vTv Therapeutics, Raises Price Target to $57
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
BTIG analyst Kambiz Yazdi maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and raises the price target from $49 to $57.
BTIG analyst Kambiz Yazdi maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and raises the price target from $49 to $57.